CytomX Therapeutics stock (US23284F1057): Recent price volatility draws attention

CytomX Therapeutics shares fell 2.32% to $3.79 on May 13, 2026, amid ongoing clinical developments in oncology. The stock shows medium risk with average daily volatility of 5.54% over the past week.

CytomX Therapeutics stock declined 2.32% on Wednesday, May 13, 2026, closing at $3.79 after trading from $3.88, according to StockInvest.us as of May 13, 2026. The biopharma company's shares reached a daily high of $3.94 and low of $3.71 during the session on Nasdaq, as reported by Robinhood as of May 13, 2026. This movement reflects short-term volatility in the clinical-stage oncology sector.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CytomX Therapeutics, Inc.
• Sector/industry: Biotechnology / Oncology
• Headquarters/country: United States
• Core markets: US, global clinical trials
• Key revenue drivers: Collaborations, PROBODY therapeutics
• Home exchange/listing venue: Nasdaq (CTMX)
• Trading currency: USD

CytomX Therapeutics: core business model

CytomX Therapeutics develops conditionally activated biologics, including PROBODY therapeutics designed to target the tumor microenvironment. The company's platform aims to improve safety and efficacy of cancer treatments by activating drugs selectively at tumor sites. This approach supports multiple collaborations with major pharmaceutical firms.

CytomX operates as a clinical-stage biopharmaceutical company focused on oncology, with a pipeline advancing through Phase 1 and 2 trials. US investors track its progress due to Nasdaq listing and exposure to the $200+ billion US oncology market.

Main revenue and product drivers for CytomX Therapeutics

Key revenue stems from partnership agreements, milestone payments, and potential royalties from PROBODY-enabled therapies. Collaborators include Amgen and Bristol Myers Squibb, providing non-dilutive funding critical for clinical biotech firms. The company's lead candidates target solid tumors, addressing unmet needs in immuno-oncology.

Pipeline highlights include CX-2051 and other masked antibodies, with data readouts influencing stock moves. For US investors, CytomX's focus on precision oncology aligns with growing demand for targeted therapies amid rising cancer incidence.

Industry trends and competitive position

The oncology biotech sector sees robust investment, with targeted therapies gaining share over traditional chemotherapy. CytomX differentiates via its PROBODY platform, potentially reducing off-tumor toxicity—a key challenge in ADCs and bispecifics. Competitors like Seagen (now Pfizer) and Genmab lead in similar spaces.

CytomX holds a niche in conditional activation, with US market relevance through FDA pathways and trial sites. Sector M&A activity, such as recent ADC deals, underscores strategic interest in such technologies.

Why CytomX Therapeutics matters for US investors

As a Nasdaq-listed biotech, CytomX offers US investors direct exposure to innovative oncology platforms without overseas listing risks. Its collaborations with US giants like Amgen bolster credibility and funding stability. The stock's volatility suits growth-oriented portfolios tracking clinical catalysts.

Risks and open questions

Biotech risks include clinical trial failures, regulatory hurdles, and funding needs amid cash burn. CytomX faces competition in crowded immuno-oncology, with trial data pivotal for valuation. Investors monitor upcoming readouts and partnership expansions.

Conclusion

CytomX Therapeutics continues advancing its PROBODY platform amid recent share price volatility, with the stock closing at $3.79 on May 13, 2026. Developments in oncology collaborations and clinical pipeline remain key focus areas for market watchers. US investors note its Nasdaq presence and sector positioning as ongoing storylines.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.